ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

ASCO Hematology

ASCO Hematology

The anti-CCR4 antibody mogamulizumab showed promising response rates compared to investigator’s choice in a randomized phase II trial of relapsed/refractory adult T-cell leukemia/lymphoma.

Two studies show that early deep responses with TKIs yield lasting positive outcomes in CML patients, and that dasatinib outperforms imatinib.

New research has shown that a higher dose of CTL019 with split dosing was associated with reduced toxicity in adult patients with relapsed, refractory CD19-positive ALL.

Crenolanib, a type I pan FLT3 inhibitor, had activity in a group of patients with FLT3-positive acute myeloid leukemia (AML), including a number of patients with FLT3 D835 mutations.

Adding bortezomib to bendamustine/rituximab significantly improves complete remission rates in previously untreated high-risk follicular lymphoma, according to a new study.

Researchers were able to identify a subset of patients with smoldering multiple myeloma who have a greater than 80% risk of progressing to myeloma within 2 years.

Monotherapy with the monoclonal antibody isatuximab was effective and well-tolerated in a small study of patients with relapsed and refractory multiple myeloma.

Pages

Subscribe to ASCO Hematology on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.